KYOCERA to Purchase Major Assets of U.S.-based Renovis Surgical Technologies, Inc.

Kyocera Corporation (TOKYO:6971) today announced that its U.S. headquarters, Kyocera International, Inc., has finalized an agreement with Renovis Surgical Technologies, Inc. (herein Renovis), a U.S.-based orthopedic and spinal medical device manufacturer and developer, to purchase the major assets of Renovis business operations relating to artificial joint and spinal products.

The assets will be transferred into a new California-based company wholly owned by Kyocera International, Inc., to be named Kyocera Medical Technologies, Inc., in March 2019.

Background and Overview Kyocera currently manufactures medical products, including artificial joints and dental implants, primarily for the Japanese market. The U.S. orthopedic implant market totals approximately US$20 billion, representing about 60% of the global market, with continued growth expected.* To grow internationally, Kyocera obtained U.S. FDA 510(k) clearance for its artificial hip joints and began selling them in the U.S. in 2017.

Renovis, founded in 2009, is a market leader in 3D-printed implants, and has developed a broad portfolio of innovative products for the U.S. market, serving the needs of orthopedic, neurological, and trauma surgeons. Renovis has experienced steady growth since its inception and has continued to develop and commercialize a wide range of products manufactured using its Tesera Trabecular Technology, a proprietary implant surface structure made using additive manufacturing. In addition, Renovis has developed an advanced bearing surface technology for joint replacement products. Kyoceras global strength and expansive research and development capabilities will accelerate the growth of these valuable technologies.


Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Kyocera plans to expand its U.S. medical equipment business through this asset purchase. The newly established company will develop high value-added products that improve patient health and quality of life through synergies between Kyoceras proprietary technologies and those purchased from Renovis.

* Based on third-party research as of December 2018


Overview of Renovis

Company name   Renovis Surgical Technologies, Inc.

Headquarters: Redlands, California, U.S.A. Development center: Austin, Texas, U.S.A.

President and CEO John C. Steinmann
Employees   44 (as of December 31, 2018)

For more information about Renovis:


Kyocera Corporation (TOKYO:6971) (, the parent and global headquarters of the Kyocera Group, was founded in 1959 as a producer of fine ceramics (also known as advanced ceramics). By combining these engineered materials with metals and integrating them with other technologies, Kyocera has become a leading supplier of semiconductor packages, industrial and automotive components, electronic devices, solar power generating systems, printers, copiers and mobile phones. During the year ended March 31, 2018, the companys consolidated net sales totaled 1.58 trillion yen (approx. US$14.9 billion). Kyocera appears on the Top 100 Global Innovators list by Clarivate Analytics and is ranked #612 on Forbes magazines 2018 Global 2000 list of the worlds largest publicly traded companies.

KYOCERA Corporation (Japan)
Corporate Communications
Doi, +81-(0)75-604-3416
[email protected]